U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry April 2022

Final
Docket Number:
FDA-2017-D-0759
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

Nanotechnology can be used in a broad array of FDA-regulated products, such as human drug products, including those that are biological products.3 Nanotechnology may be used to create drug products in which nanomaterials (as explained in section II of this document), serve a variety of functions, as active ingredients4 or inactive ingredients, including carriers loaded with an active ingredient. The inclusion of such materials may result in product attributes that differ from those of products that do not contain such materials, and thus may merit particular examination. This document provides guidance on the development of human drug products, including those that are biological products, in which a nanomaterial is present in the finished dosage form.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2017-D-0759.

 
Back to Top